Study on Antifungal Prophylaxis in High Risk Hematology patients FRESH-PEF73349-en Laurie LEVY-BACHELOT Study on Antifungal Prophylaxis in High Risk Hematology patients SAPHIR FRESH-PEF73349-en 73349 FRESH-PEF73349 Thierry ALLAVOINE MSD FRANCE Epidemiology France Portal (PEF) MSD FRANCE null Hematology Neoplasms The primary objective is to describe, in French hematological services, the monitoring and the therapeutic management of patients at high risk of IFDs under AF prophylaxis in real life clinical practices (imaging and laboratory exams for IFD diagnoses and surveillance, AF therapy prescribed, Therapeutic Drug Monitoring performed, facility environment). null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria : In each center, all patients meeting the following criteria will be solicited to participate to the study. 1. Male or female adult patient, aged of 18 years old or more 2. Subject undergoing myelosuppressive intensive chemotherapy for AML with present or expected profound and prolonged neutropenia* 3. Initiating a systemic** antifungal prophylaxis (J0 = 1St day of administration of the AF) 4. Accepting to participate to the study * : Profound and prolonged neutropenia is define by an absolute value of neutrophils < 500/mm3 during 10 days ** : A systemic antifungal prophylaxis is defined by a treatment provided per os or in i.v. An oral suspension can be considered as a systemic use in function of the dose used (example: fluconazole ≥ 800mg/j is considered as a systemic treatment) Patients meeting the following criteria should not be included 1. Patient refusing to participate to the study.criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study. Clinical data Participant-reported health data Other < 500 individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study 400 Unknown To be defined Access not yet planned